VIKING THERAPEUTICS INC

VKTXNASDAQ

🏆 #1279 by market capEarnings Oct 20 · PostUS Equity

$33.80▼ $0.64 (−1.90%)

Market closed · at close

1h—

24h▼ 1.9%

7d▲ 0.8%

14d▲ 1.0%

30d▼ 11.4%

1y▼ 15.2%

🏦Market Cap

$3.94B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $33.48 – $34.22
52-Week Range: $22.96 – $43.15
Volume: $3.81B
Avg Volume: $3.65B
Shares Outstanding: 116.7M
Next Earnings: Oct 27, 2026

Fundamentals Snapshot

Annual Revenue: $406M
Last Q Revenue: $103M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-4.66
Dividend Yield: —

Why Investors Own VKTX

✓High-growth profile — revenue up +32.0% YoY with expanding US Equity exposure.
✓Healthy economics — 52% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$406M▲ +26.2% YoY

Gross Margin (TTM)

52.0%▲ +1.3% YoY

Operating Income (TTM)

$148M▲ +26.2% YoY

Free Cash Flow (TTM)

$57M▲ +26.2% YoY

About VIKING THERAPEUTICS INC

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

🦦